Third quarter report Q3-2022
· Successful outcome of trial 0206, a phase 2 pharmacokinetics trial in children undergoing elective surgical procedures · First patient dosed in pivotal trial 0205 in adult patients · Cash position at the end of Q3 is dkk 15 mill – further extended by successful execution of rights issue after the period raising approximately dkk 14,7 mill before transaction costsCessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 July – 30 September 2022. The third quarter report is available as an attached document to this press release and on www.cessatech.com